SAFETY DATA SHEET

Montelukast Granules Formulation

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Montelukast Granules Formulation

Manufacturer or supplier’s details

Company: MSD

Address: 26 Talavera Road, Talavera Corp Centre, Macquarie Park New South Wales, 2113 Australia

Telephone: (61)-02-8988-8000

Emergency telephone number: (61)-02-8988-8000

E-mail address: EHSDATASTEWARD@msd.com

Telefax: 908-735-1496

Recommended use of the chemical and restrictions on use

Recommended use: Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification

Not a hazardous substance or mixture.

GHS label elements

Not a hazardous substance or mixture.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture: Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Montelukast</td>
<td>151767-02-1</td>
<td>&lt; 10</td>
</tr>
</tbody>
</table>

SECTION 4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air.
**SAFETY DATA SHEET**

**Montelukast Granules Formulation**

---

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
</table>

- **In case of skin contact**: Get medical attention if symptoms occur. Wash with water and soap.
- **In case of eye contact**: Get medical attention if symptoms occur. If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
- **If swallowed**: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
- **Most important symptoms and effects, both acute and delayed**: Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.
- **Protection of first-aiders**: No special precautions are necessary for first aid responders.
- **Notes to physician**: Treat symptomatically and supportively.

---

### SECTION 5. FIREFIGHTING MEASURES

- **Suitable extinguishing media**: Water spray, Alcohol-resistant foam, Carbon dioxide (CO2), Dry chemical.
- **Unsuitable extinguishing media**: None known.
- **Specific hazards during firefighting**: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
- **Hazardous combustion products**: Carbon oxides.
- **Specific extinguishing methods**: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
- **Special protective equipment for firefighters**: Wear self-contained breathing apparatus for firefighting if necessary. Use personal protective equipment.

---

### SECTION 6. ACCIDENTAL RELEASE MEASURES

- **Personal precautions, protective equipment and emergency procedures**: Follow safe handling advice and personal protective equipment recommendations.
- **Environmental precautions**: Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
- **Methods and materials for containment and cleaning up**: Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces...
with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling: Do not breathe dust. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage: Keep in properly labelled containers. Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types: Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Montelukast</td>
<td>151767-02-1</td>
<td>TWA</td>
<td>40 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>400 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>
Montelukast Granules Formulation

Engineering measures: All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type: Particulates type

Hand protection: Chemical-resistant gloves

Eye protection: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: powder

Colour: No data available

Odour: No data available

Odour Threshold: No data available

pH: No data available

Melting point/freezing point: No data available

Initial boiling point and boiling range: No data available

Flash point: Not applicable

Evaporation rate: No data available

Flammability (solid, gas): May form explosive dust-air mixture during processing, handling or other means.
SAFETY DATA SHEET
Montelukast Granules Formulation

Version: 2.14  Revision Date: 09/13/2019  SDS Number: 22981-00017  Date of last issue: 24.04.2019
Date of first issue: 17.10.2014

Flammability (liquids) : No data available
Upper explosion limit / Upper flammability limit : No data available
Lower explosion limit / Lower flammability limit : No data available
Vapour pressure : No data available
Relative vapour density : No data available
Relative density : No data available
Density : No data available
Solubility(ies)
Water solubility : No data available
Partition coefficient: n-octanol/water : No data available
Auto-ignition temperature : No data available
Decomposition temperature : No data available
Viscosity
Viscosity, kinematic : No data available
Explosive properties : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Molecular weight : No data available
Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY
Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions
: May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid : Heat, flames and sparks. Avoid dust formation.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.
SECTION 11. TOXICOLOGICAL INFORMATION

Exposure routes:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Not classified based on available information.

Components:

Montelukast:
- Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg
- LD50 (Mouse): > 5,000 mg/kg
- Acute inhalation toxicity: Remarks: No data available
- Acute dermal toxicity: Remarks: No data available

Skin corrosion/irritation
Not classified based on available information.

Components:

Montelukast:
- Species: Rabbit
- Result: Mild skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Montelukast:
- Species: Rabbit
- Result: Severe irritation

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:

Montelukast:
- Remarks: No data available
Chronic toxicity

Germ cell mutagenicity
Not classified based on available information.

Product:
Genotoxicity in vitro
: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster fibroblasts
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells
Result: negative

Test Type: Alkaline elution assay
Test system: rat hepatocytes
Result: negative

Genotoxicity in vivo
: Test Type: Chromosomal aberration
Species: Mouse
Cell type: Bone marrow
Application Route: Oral
Result: negative

Components:

Montelukast:
Genotoxicity in vitro
: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster fibroblasts
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells
Result: negative

Test Type: Alkaline elution assay
Test system: rat hepatocytes
Result: negative

Genotoxicity in vivo
: Test Type: Chromosomal aberration
Species: Mouse
Cell type: Bone marrow
Application Route: Oral
Result: negative

Carcinogenicity
Not classified based on available information.
SAFETY DATA SHEET

Montelukast Granules Formulation

Version: 2.14
Revision Date: 09/13/2019
SDS Number: 22981-00017
Date of last issue: 24.04.2019
Date of first issue: 17.10.2014

**Product:**
Species: Rat
Application Route: Oral
Exposure time: 2 Years
Dose: 200 mg/kg body weight
Result: negative

Species: Mouse
Application Route: Oral
Exposure time: 92 weeks
Dose: 100 mg/kg body weight
Result: negative

**Components:**

**Montelukast:**
Species: Rat
Application Route: Oral
Exposure time: 2 Years
Result: negative

Species: Mouse
Application Route: Oral
Exposure time: 92 weeks
Result: negative

**Reproductive toxicity**

Not classified based on available information.

**Product:**
Effects on fertility: Test Type: Fertility
Species: Rat, male
Application Route: Oral
Fertility: NOAEL Parent: 800 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Test Type: Fertility
Species: Rat, female
Application Route: Oral
Fertility: LOAEL Parent: 200 mg/kg body weight
Symptoms: Reduced fertility

**Components:**

**Montelukast:**
Effects on fertility: Test Type: Fertility
Species: Rat, male
Application Route: Oral
Fertility: NOAEL: 800 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Test Type: Fertility
Species: Rat, female
Application Route: Oral
Fertility: LOAEL: 200 mg/kg body weight
Symptoms: Reduced fertility

Test Type: Fertility
Species: Rat, female
Application Route: Oral
Fertility: NOAEL: 100 mg/kg body weight
Symptoms: Reduced fertility

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
Not classified based on available information.

Repeated dose toxicity

Components:

Montelukast:
Species: Monkey, male and female
NOAEL: 150 - 300 mg/kg
Application Route: Oral
Exposure time: 53 Weeks
Remarks: No significant adverse effects were reported

Species: Rat
NOAEL: 50 mg/kg
Application Route: Oral
Exposure time: 53 Weeks
Remarks: No significant adverse effects were reported

Species: Mouse
NOAEL: 50 mg/kg
Application Route: Oral
Exposure time: 14 Weeks
Remarks: No significant adverse effects were reported

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Product:
Skin contact: Remarks: May irritate skin.
Eye contact: Symptoms: Severe irritation
Ingestion: Symptoms: upper respiratory tract infection, pharyngitis, Headache, Cough, Abdominal pain, Diarrhoea, Fever

Components:

Montelukast:
Skin contact: Remarks: May irritate skin.
Eye contact: Symptoms: Severe irritation
Ingestion: Symptoms: upper respiratory tract infection, pharyngitis, headache, cough, abdominal pain, diarrhoea, fever

**SECTION 12. ECOLOGICAL INFORMATION**

**Ecotoxicity**

**Components:**

**Montelukast:**

- **Toxicity to fish**: LC50 (Pimephales promelas (fathead minnow)): > 0.0778 mg/l
  - Exposure time: 96 h
  - Method: OECD Test Guideline 203
  - Remarks: No toxicity at the limit of solubility

- **Toxicity to daphnia and other aquatic invertebrates**: EC50 (Daphnia magna (Water flea)): > 0.0675 mg/l
  - Exposure time: 48 h
  - Method: OECD Test Guideline 202
  - Remarks: No toxicity at the limit of solubility

- **Toxicity to algae/aquatic plants**: NOEC (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201
  - Remarks: No toxicity at the limit of solubility

  EC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201
  - Remarks: No toxicity at the limit of solubility

- **Toxicity to fish (Chronic toxicity)**: NOEC (Pimephales promelas (fathead minnow)): 0.073 mg/l
  - Exposure time: 32 d
  - Method: OECD Test Guideline 210
  - Remarks: No toxicity at the limit of solubility

  NOEC (Cyprinodon variegatus (sheepshead minnow)): 0.0816 mg/l
  - Exposure time: 7 d
  - Remarks: No toxicity at the limit of solubility

- **Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)**: NOEC (Daphnia magna (Water flea)): 0.23 mg/l
  - Exposure time: 21 d
  - Remarks: No toxicity at the limit of solubility

- **Toxicity to microorganisms**: EC50: > 100 mg/l
  - Exposure time: 3 h
  - Test Type: Respiration inhibition
  - Method: OECD Test Guideline 209
  - Remarks: No toxicity at the limit of solubility
Montelukast Granules Formulation

Persistence and degradability

Components:

Montelukast:
Biodegradability: Result: not rapidly degradable
Biodegradation: 0 %
Exposure time: 28 d

Stability in water: Hydrolysis: 50 % (21.7 h)

Bioaccumulative potential

Components:

Montelukast:
Partition coefficient: n-octanol/water: log Pow: > 4.3

Mobility in soil
No data available

Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

National Regulations

ADG
Not regulated as a dangerous good
SAFETY DATA SHEET

Montelukast Granules Formulation

Version 2.14 Revision Date: 09/13/2019 SDS Number: 22981-00017 Date of last issue: 24.04.2019

Date of first issue: 17.10.2014

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Prohibition/Licensing Requirements : There is no applicable prohibition or notification/licensing requirements, including for carcinogens under Commonwealth, State or Territory legislation.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information

Revision Date : 09/13/2019


Date format : dd.mm.yyyy

Full text of other abbreviations

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Develop-
SAFETY DATA SHEET

Montelukast Granules Formulation

Version 2.14  Revision Date: 09/13/2019  SDS Number: 22981-00017  Date of last issue: 24.04.2019

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AU / EN